Bio-modulators in platelet-rich plasma: a comparison of the amounts in products from healthy donors and patients produced with three different techniques.
Gianluca Ubezio, Massimo Ghio, Paola Contini, Roberta Bertorello, Gennaro Marino, Andrea Tomasini, Gino Tripodi
Author Information
Gianluca Ubezio: Department of Internal Medicine, I.R.C.C.S. "A.O.U. San Martino-IST" and University of Genoa, Genoa, Italy.
Massimo Ghio: Department of Internal Medicine, I.R.C.C.S. "A.O.U. San Martino-IST" and University of Genoa, Genoa, Italy.
Paola Contini: Department of Internal Medicine, I.R.C.C.S. "A.O.U. San Martino-IST" and University of Genoa, Genoa, Italy.
Roberta Bertorello: Immunohaematology and Transfusion Medicine Unit, Santa Corona Hospital ASL2, Savona, Italy.
Gennaro Marino: Immunohaematology and Transfusion Medicine Unit, Santa Corona Hospital ASL2, Savona, Italy.
Andrea Tomasini: Immunohaematology and Transfusion Medicine Unit, Santa Corona Hospital ASL2, Savona, Italy.
Gino Tripodi: Immunohematology and Transfusion Centre, Istituto Giannina Gaslini, Genoa, Italy.
BACKGROUND: Platelet-rich plasma consists of platelets concentrated in a small volume of plasma and constitutes a reservoir of bio-modulators potentially useful in tissue repair. The amounts of bio-modulators detectable in platelet-rich plasma prepared with various commercial or "in house" methods have been reported, but virtually all the analyses described have been performed on platelet-rich plasma derived from healthy donors. Since leucocyte contamination is technically unavoidable, we investigated whether platelet-rich plasma prepared from patients could contain different amounts of bio-modulators because of a possible activated status of the leucocytes. MATERIALS AND METHODS: We evaluated platelet-rich plasma prepared with three different techniques (the commercial Vivostat and Biomet recover GPS II systems and an "in house" method) starting from whole blood from healthy donors and patients. Specifically, we compared the levels of sHLA-I, sFasL, platelet-derived growth factor, transforming growth factors-beta and vascular endothelial growth factor in the platelet-rich plasma releasates according to the method of preparation and to the immune system activation status of the subjects. RESULTS: With the exception of sHLA-I levels, no differences were found in the surrogate indices of lymphocyte activation between healthy donors and patients. No significant differences were found in sHLA-I, sFasL, platelet-derived growth factor, transforming growth factors-beta and vascular endothelial growth factor levels detectable in platelet-rich plasma produced with the three different methods in either healthy donors or patients. DISCUSSION: On the whole our findings indicate that the overall content of bio-modulators in autologous platelet-rich plasma is not influenced by T-lymphocyte activation status, at least in patients with uncomplicated femoral fractures. The amounts of sFasL and sHLA-I detected in all the platelet-rich plasma releasates studied were very small, far below the amounts detectable in all clinically available blood derivatives and absolutely insufficient to induce sHLA-I and/or sFasL mediated immunomodulation.
References
Int Immunol. 2000 Feb;12(2):195-203
[PMID: 10653855]
